# Bone Scintigraphy for Metastatic Disease

## Overview

Whole-body bone scintigraphy is the most widely used screening test for skeletal metastases. It detects the osteoblastic response to metastatic disease rather than the tumor cells themselves. Common indications include staging and surveillance of breast cancer, prostate cancer, and lung cancer. Bone scintigraphy is increasingly being challenged by PET-based agents such as F-18 sodium fluoride and PSMA PET.

## Mechanism of Uptake

Tc-99m MDP and HDP adsorb onto hydroxyapatite at sites of active bone formation. Because the scan detects the osteoblastic reaction to metastatic disease rather than the tumor cells directly, sensitivity is highest for osteoblastic and mixed lesions. Purely lytic lesions with minimal osteoblastic reaction, as seen in renal cell carcinoma, multiple myeloma, and thyroid cancer, may produce false negative results.

## Technique

Whole-body anterior and posterior planar imaging is performed at 2 to 4 hours post-injection, allowing time for blood pool clearance. Adequate hydration and voiding before imaging are important. Spot views of areas of interest are obtained as needed. SPECT/CT should be performed for equivocal findings, as it markedly improves specificity.

<image>Normal whole-body bone scan (anterior and posterior views) showing symmetric uptake in the skeleton with normal renal excretion and bladder activity</image>

## Patterns of Metastatic Disease

### Multiple Random Lesions

The most common pattern of skeletal metastasis is multiple foci of increased uptake distributed randomly in the axial and appendicular skeleton, not following a degenerative pattern. This pattern is highly specific for metastatic disease and is most commonly seen in prostate and breast cancer.

### Solitary Lesion

Approximately 50 to 60% of solitary bone scan lesions in cancer patients are metastatic. Location influences the probability: uptake in the vertebral body, pedicle, or posterior elements has a higher likelihood of representing metastasis. Rib lesions, especially posteriorly, can be either metastatic or traumatic. Skull and sternum lesions are more likely metastatic in oncology patients. A solitary lesion requires correlation with CT, MRI, or SPECT/CT for characterization, and follow-up imaging in 3 to 6 months or advanced imaging should be considered if the finding remains equivocal.

### Superscan

A superscan presents as diffusely increased skeletal uptake with absent or very faint renal and soft tissue activity. It can appear deceptively "beautiful" because the skeleton is so uniformly and intensely visualized. Causes include diffuse skeletal metastases (most commonly from prostate cancer, also breast cancer), metabolic bone disease (renal osteodystrophy, hyperparathyroidism), and myeloproliferative disorders. The key diagnostic clue is the absence of normal renal activity, which becomes obscured by the intense bone uptake.

### Flare Phenomenon

The flare phenomenon is a paradoxical increase in the number and intensity of bone scan lesions after initiation of effective systemic therapy. It occurs in the first 2 to 12 weeks after starting chemotherapy or hormonal therapy and represents the osteoblastic healing response in responding metastases. It must be distinguished from true disease progression. Subsequent scans show improvement if the flare interpretation is correct, whereas progressive disease would continue to worsen. Clinical context is essential: improving symptoms and declining tumor markers support a flare rather than progression.

<image>Flare phenomenon: baseline bone scan showing multiple metastases, 8-week post-treatment scan showing apparent worsening (flare), and 6-month scan showing marked improvement confirming treatment response</image>

## Cancer-Specific Considerations

### Prostate Cancer

Prostate cancer is the cancer most commonly associated with osteoblastic metastases. Bone scintigraphy is the standard staging study when PSA exceeds 20 ng/mL, the Gleason score is 8 or higher, or the clinical stage is T3 or T4. PSMA PET/CT is increasingly replacing bone scintigraphy for prostate cancer because of its higher sensitivity and specificity. The superscan pattern is particularly characteristic of diffuse prostatic skeletal metastases.

### Breast Cancer

Breast cancer produces mixed osteoblastic and lytic metastases, and bone scintigraphy detects most of them. It is indicated for staging in symptomatic patients or those with advanced disease. The flare phenomenon is common after starting endocrine therapy. FDG PET/CT may complement bone scintigraphy for detecting lytic disease that the bone scan might miss.

### Lung Cancer

Bone scintigraphy is used for staging non-small cell lung cancer, particularly when PET/CT is not available. FDG PET/CT has largely replaced bone scanning for lung cancer staging. Bone scintigraphy may be complementary for detecting osteoblastic metastases that FDG PET occasionally misses.

| Cancer Type | Metastasis Type | Bone Scan Sensitivity | Preferred Alternative |
|---|---|---|---|
| Prostate | Osteoblastic | High (85–90%) | PSMA PET/CT increasingly preferred |
| Breast | Mixed (blastic/lytic) | Good (75–85%) | FDG PET/CT for lytic disease |
| Lung (NSCLC) | Mixed/lytic | Moderate (70–80%) | FDG PET/CT preferred |
| Renal cell carcinoma | Predominantly lytic | Low (30–50%) | CT or FDG PET/CT |
| Thyroid cancer | Predominantly lytic | Low (30–50%) | RAI scan or FDG PET/CT |
| Multiple myeloma | Purely lytic | Very low (<30%) | Low-dose whole-body CT or FDG PET |

### Renal Cell Carcinoma and Thyroid Cancer

These cancers produce predominantly lytic metastases with minimal osteoblastic reaction. Bone scintigraphy has low sensitivity of only 30 to 50%, and many metastases are missed. FDG PET/CT or cross-sectional imaging with CT or MRI is preferred.

### Multiple Myeloma

Bone scintigraphy is not indicated for multiple myeloma because the disease is predominantly lytic with minimal osteoblastic activity. The scan may be negative even with extensive disease. The skeletal survey, low-dose whole-body CT, or FDG PET/CT are the standard imaging approaches.

## F-18 NaF PET/CT

### Mechanism

F-18 sodium fluoride PET/CT works by the same fundamental mechanism as Tc-99m MDP: the fluoride ion substitutes for the hydroxyl group in the hydroxyapatite crystal. However, PET imaging provides superior spatial resolution and sensitivity. F-18 NaF has faster bone uptake and blood clearance than Tc-99m MDP.

### Advantages Over Tc-99m Bone Scan

F-18 NaF PET/CT has higher sensitivity (95 to 100% versus 75 to 85% for Tc-99m bone scan) and higher specificity when combined with CT. Image quality is better, imaging time is shorter, and smaller and earlier metastatic lesions can be detected.

### Controversy

Whether F-18 NaF PET/CT should replace Tc-99m bone scanning for routine metastatic surveys remains debated. It has higher cost and is less widely available. The radiation dose is comparable to that of a Tc-99m bone scan. The incremental clinical benefit is questionable when FDG PET/CT or PSMA PET/CT is already being performed.

<image>Comparison of Tc-99m MDP whole-body bone scan and F-18 NaF PET/CT in the same patient with prostate cancer metastases, showing superior lesion detection and characterization on NaF PET/CT</image>

## SPECT/CT Added Value

SPECT/CT converts equivocal planar findings to definitive diagnoses in 30 to 50% of cases. It distinguishes benign from malignant lesions by correlating metabolic activity with CT morphology. It is particularly useful for the spine (differentiating degenerative from metastatic disease), ribs, and pelvis. SPECT/CT should be performed for any equivocal lesion identified on the planar bone scan.

## Differentiating Metastases from Benign Conditions

### Degenerative Disease

Degenerative changes typically involve joints, endplates, and facets in a symmetric pattern. Osteophyte formation is visible on CT or radiographs. Uptake at vertebral body margins reflects endplate degenerative change, whereas uptake in the vertebral body itself or the pedicle suggests metastasis.

### Fractures

Fractures produce a linear uptake pattern following the fracture line. Rib fractures may be traumatic, stress, or pathologic. Vertebral compression fractures may be osteoporotic or pathologic, and MRI or biopsy may be needed if the distinction is uncertain.

### Paget Disease

Paget disease produces intense uptake with bone expansion. Classic locations include the pelvis, femur, tibia, skull, and spine. The expanded cortex and coarsened trabecular pattern on CT distinguish it from metastatic disease.

### Fibrous Dysplasia

Fibrous dysplasia shows focal uptake in expanded bone with a ground-glass CT appearance. It is usually monostotic, though polyostotic forms can mimic metastatic disease.

## Clinical Pearls

Multiple randomly distributed lesions in an oncology patient are metastatic until proven otherwise.

A superscan can be mistaken for a "normal" scan if the reader does not notice the absence of renal activity.

The flare phenomenon must be distinguished from disease progression. Clinical and biochemical correlation is essential.

Bone scintigraphy is insensitive for purely lytic lesions such as those from myeloma, renal cell carcinoma, and thyroid cancer. It should not be relied upon for these cancers.

SPECT/CT should be obtained for any equivocal lesion. It dramatically improves specificity.

Solitary rib lesions in oncology patients are metastatic in approximately 50% of cases but can also represent fractures or benign disease.

The hot pedicle sign, in which there is uptake in a vertebral pedicle, is highly suspicious for metastatic disease.

## References

- SNMMI Procedure Standard for Bone Scintigraphy.
- Defined Role of Bone Scan in Metastatic Disease. *Seminars in Nuclear Medicine*, 2010.
- Defined Comparison of F-18 NaF PET/CT vs. Tc-99m Bone Scan. *Journal of Nuclear Medicine*, 2016.
- NCCN Guidelines: Bone Metastasis Imaging Recommendations.